ADSL and bacterial infectious disease: To date, more than 3000 AMPs have been characterized (Peptide Database: http://aps.unmc.edu/AP/main.php, accessed on 10 September 2021) and only seven of them have been approved by the U.S. Food and Drug Administration (FDA), mostly for topical applications or to systemically treat severe bacterial infections [37,38].